Consensus in stem cell transplantation for pediatric lymphomas
DOI:
https://doi.org/10.46765/2675-374X.2025v6n1e304Keywords:
Pediatrics, Stem Cell Transplantation, LymphomaAbstract
Lymphomas are the third most common childhood cancer in Brazil. Management is predicated on precise diagnosis and staging through clinical, pathological, molecular, and radiological evaluation. Although the prognosis for pediatric non-Hodgkin and Hodgkin lymphoma has improved markedly, relapsed or refractory cases remain a clinical challenge. For these patients, aggressive chemotherapy followed by autologous or allogeneic hematopoietic cell transplantation serves as a vital salvage strategy. The Pediatric Group of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy has revised its current consensus, providing updated recommendations for indications and conditioning protocols. This revision also includes the assessment of new therapeutic strategies, including immunotherapy and CAR-T cell therapy, for eligible patients.
References
1. Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação de Prevenção e Vigilância. Incidência, mortalidade e morbidade hospitalar por câncer em crianças, adolescentes e adultos jovens no Brasil: informações dos registros de câncer e do sistema de mortalidade. Rio de Janeiro: Instituto Nacional de Câncer José Alencar Gomes da Silva; 2016.
2. PDQ Pediatric Treatment Editorial Board. Childhood Hodgkin lymphoma treatment (PDQ®): health professional version. PDQ cancer information summaries. Bethesda: National Cancer Institute; 2002–2021.
3. Kuwahara CC, Zamperlini Neto G, Michalowski MB, Ginani VC, Breviglieri CNM. Hematopoietic stem cell transplantation for pediatric lymphomas. J Bone Marrow Transplant Cell. 2021;2(4):135. https://doi.org/10.46765/2675-374X.2021v2n4p135 DOI: https://doi.org/10.46765/2675-374X.2021v2n4p135
4. Cairo M, Auperin A, Perkins SL, Pinkerton R, Harrison L, Goldman S, Patte C. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group. Br J Haematol. 2018;182(6):859–69. https://doi.org/10.1111/bjh.15491 DOI: https://doi.org/10.1111/bjh.15491
5. Burkhardt B, Taj M, Garnier N, Minard-Colin V, Hazar V, Mellgren K, Osumi T, Fedorova A, Myakova N, Verdu-Amoros J, Andres M, Kabickova E, Attarbaschi A, Chiang AKS, Bubanska E, Donska S, Hjalgrim LL, Wachowiak J, Pieczonka A, Uyttebroeck A, Lazic J, Loeffen J, Buechner J, Niggli F, Csoka M, Krivan G, Palma J, Burke GAA, Beishuizen A, Koeppen K, Mueller S, Herbrueggen H, Woessmann W, Zimmermann M, Balduzzi A, Pillon M. Treatment and outcome analysis of 639 relapsed non-Hodgkin lymphomas in children and adolescents and resulting treatment recommendations. Cancers. 2021;13(9):2075. https://doi.org/10.3390/cancers13092075 DOI: https://doi.org/10.3390/cancers13092075
6. Woessmann W, Zimmermann M, Meinhardt A, Müller S, Hauch H, Knörr F, Oschlies I, Klapper W, Niggli F, Kabickova E, Attarbaschi A, Reiter A, Burkhardt B. Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy. Blood. 2020;135(14):1124–32. https://doi.org/10.1182/blood.2019003591 DOI: https://doi.org/10.1182/blood.2019003591
7. Moleti ML, Testi AM, Foà R. Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2020;189(5):826–43. https://doi.org/10.1111/bjh.16461 DOI: https://doi.org/10.1111/bjh.16461
8. Rivers J, Annesley C, Summers C, Finney O, Pulsipher MA, Wayne AS, Park JR, Jensen MC, Gardner R. Early response data for pediatric patients with non-Hodgkin lymphoma treated with CD19 chimeric antigen receptor (CAR) T-cells. Blood. 2018;132(Suppl.1):2957. https://doi.org/10.1182/blood-2018-99-113744 DOI: https://doi.org/10.1182/blood-2018-99-113744
9. Zhang WQ, Hu B, Jin L, Yang J, Du J, Wang S, Ren YL, Liu Y, Zhang YH. Chimeric antigen receptor t‐cells (car‐t) for refractory and relapsed burkitt’s lymphoma: early response in pediatric patients. Hematol Oncol. 2018;59–60. https://doi.org/10.1002/hon.28_2629 DOI: https://doi.org/10.1002/hon.28_2629
10. Lowe EJ, Gross TG. Anaplastic large cell lymphoma in children and adolescents. Pediatr Hematol Oncol. 2013 Sep;30(6):509–19. DOI: https://doi.org/10.3109/08880018.2013.805347
11. Woessmann W, Zimmermann M, Lenhard M, Burkhardt B, Rossig C, Kremens B, Lang P, Attarbaschi A, Mann G, Oschlies I, Klapper W, Reiter A. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(22):3065–71. https://doi.org/10.1200/jco.2011.34.8417 DOI: https://doi.org/10.1200/JCO.2011.34.8417
12. Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS, Hayashi RJ, Termuhlen AM, Zhang MJ, Davies SM, Eapen M. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2010;16(2):223–30. https://doi.org/10.1016/j.bbmt.2009.09.021 DOI: https://doi.org/10.1016/j.bbmt.2009.09.021
13. Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, Pillon M, Aladjidi N, Klingebiel T, Landman-Parker J, Medina-Sanson A, August K, Sachs J, Hoffman K, Kinley J, Song S, Song G, Zhang S, Suri A, Gore L. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018; 5(10): e450–61. https://doi.org/10.1016/s2352-3026(18)30153-4 DOI: https://doi.org/10.1016/S2352-3026(18)30153-4
14. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(18):2190–6. https://doi.org/10.1200/jco.2011.38.0402 DOI: https://doi.org/10.1200/JCO.2011.38.0402
15. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709–17. https://doi.org/10.1182/blood-2017-05-780049 DOI: https://doi.org/10.1182/blood-2017-05-780049
16. Marks LJ, Ritter V, Agrusa JE, Kamdar KY, Rivers J, Gardner R, Ehrhardt MJ, Devine KJ, Phillips CA, Reilly A, August K, Weinstein J, Satwani P, Forlenza CJ, Smith CM, Greer C, Afify Z, Lin CH, Belsky JA, Ding H, Hoogstra D, Toner K, Link MP, Schultz LM, Lowe EJ, Aftandilian C. Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era. Blood Adv. 2025; 9(6):1356–65. https://doi.org/10.1182/bloodadvances.2024014745 DOI: https://doi.org/10.1182/bloodadvances.2024014745
17. Brugières L, Pacquement H, Le Deley MC, Leverger G, Lutz P, Paillard C, Baruchel A, Frappaz D, Nelken B, Lamant L, Patte C. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(30):5056–61. https://doi.org/10.1200/jco.2008.20.1764 DOI: https://doi.org/10.1200/JCO.2008.20.1764
18. Knörr F, Brugières L, Pillon M, Zimmermann M, Ruf S, Attarbaschi A, Mellgren K, Burke GAA, Uyttebroeck A, Wróbel G, Beishuizen A, Aladjidi N, Reiter A, Woessmann W; European Inter-Group for Childhood Non-Hodgkin Lymphoma. Stem cell transplantation and vinblastine monotherapy for relapsed pediatric anaplastic large cell lymphoma: results of the international, prospective ALCL-relapse trial. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(34):3999–4009. https://doi.org/10.1200/jco.20.00157 DOI: https://doi.org/10.1200/JCO.20.00157
19. Kada A, Fukano R, Mori T, Kamei M, Tanaka F, Ueyama J, Sekimizu M, Osumi T, Mori T, Koga Y, Ohki K, Fujita N, Mitsui T, Saito AM, Hashimoto H, Kobayashi R. A multicenter, open-label, clinical trial to assess the effectiveness and safety of allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning in relapsed/refractory anaplastic large-cell lymphoma in children. Acta Med Okayama. 2020;74(1):89–94. https://doi.org/10.18926/amo/57959
20. Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, Riehm H, Schrappe M, Reiter A; BFM Group. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131(1):39–49. https://doi.org/10.1111/j.1365-2141.2005.05735.x DOI: https://doi.org/10.1111/j.1365-2141.2005.05735.x
21. Si Lim SJ, Ford JB, Hermiston ML. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults. Blood. 2023;141(25):3019–30. https://doi.org/10.1182/blood.2022016503 DOI: https://doi.org/10.1182/blood.2022016503
22. Morita-Fujita M, Arai Y, Yoshioka S, Ishikawa T, Kanda J, Kondo T, Akasaka T, Ueda Y, Imada K, Moriguchi T, Yago K, Kitano T, Yonezawa A, Nohgawa M, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group (KSCTG). Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies. Sci Rep. 2020;10(1):21418. https://doi.org/10.1038/s41598-020-78334-x DOI: https://doi.org/10.1038/s41598-020-78334-x
23. Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, Getz KD, Brogdon JL, Fesnak AD, Siegel DL, Davis MM, Bartoszek C, Lacey SF, Hexner EO, Chew A, Wertheim GB, Levine BL, June CH, Grupp SA, Maude SL. Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(27):3044–55. https://doi.org/10.1200/jco.20.03458 DOI: https://doi.org/10.1200/JCO.20.03458
24. Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2011;17(3):412–20. https://doi.org/10.1016/j.bbmt.2010.07.016 DOI: https://doi.org/10.1016/j.bbmt.2010.07.016
25. Sureda A, Mataix R, Hernández-Navarro F, Jarque I, Lahuerta JJ, Tomás JF, Brunet S, Caballero D, Conde E, León A, Fernández MN, López A, Maldonado J, Bengoechea E, Callís M, Carrera D, García-Conde J, García-Laraña J, Moraleda JM, Morey M, Rifón J, Sierra J, Torres A, Domingo-Albós A. Autologous stem cell transplantation for poor prognosis Hodgkin’s disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group. Bone Marrow Transplant. 1997;20(4):283–8. https://doi.org/10.1038/sj.bmt.1700886 DOI: https://doi.org/10.1038/sj.bmt.1700886
26. Woessmann W, Peters C, Lenhard M, Burkhardt B, Sykora KW, Dilloo D, Kremens B, Lang P, Führer M, Kühne T, Parwaresch R, Ebell W, Reiter A. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report. Br J Haematol. 2006;133(2):176–82. https://doi.org/10.1111/j.1365-2141.2006.06004.x DOI: https://doi.org/10.1111/j.1365-2141.2006.06004.x
27. Perales MA, Ahmed S. When to use stem cell transplantation for classical Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program. 2024;2024(1):517–23. https://doi.org/10.1182/hematology.2024000575 DOI: https://doi.org/10.1182/hematology.2024000575
28. Daw S, Hasenclever D, Mascarin M, Fernández-Teijeiro A, Balwierz W, Beishuizen A, Burnelli R, Cepelova M, Claviez A, Dieckmann K, Landman-Parker J, Kluge R, Körholz D, Mauz-Körholz C, Wallace WH, Leblanc T. Risk and response adapted treatment guidelines for managing first relapsed and refractory classical Hodgkin lymphoma in children and young people. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group. HemaSphere. 2020;4(1):e329. https://doi.org/10.1097/hs9.0000000000000329 DOI: https://doi.org/10.1097/HS9.0000000000000329
29. Shah GL, Yahalom J, Matasar MJ, Verwys SL, Goldman DA, Bantilan KS, Zhang Z, McCall SJ, Moskowitz AJ, Moskowitz CH. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. Br J Haematol. 2016;175(3):440–7. https://doi.org/10.1111/bjh.14245 DOI: https://doi.org/10.1111/bjh.14245
30. Adams HJA, Nievelstein RAJ, Kwee TC. Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy. Ann Hematol. 2016;95(1):1–9. https://doi.org/10.1007/s00277-015-2529-2 DOI: https://doi.org/10.1007/s00277-015-2529-2
31. Perales MA, Ceberio I, Armand P, Burns LJ, Chen R, Cole PD, Evens AM, Laport GG, Moskowitz CH, Popat U, Reddy NM, Shea TC, Vose JM, Schriber J, Savani BN, Carpenter PA; American Society for Blood and Marrow Transplantation. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21(6):971–83. https://doi.org/10.1016/j.bbmt.2015.02.022 DOI: https://doi.org/10.1016/j.bbmt.2015.02.022
32. Forlenza CJ, Gulati N, Mauguen A, Absalon MJ, Castellino SM, Franklin A, Keller FG, Shukla N. Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma. Blood Adv. 2021;5(24):5519–24. https://doi.org/10.1182/bloodadvances.2021005268 DOI: https://doi.org/10.1182/bloodadvances.2021005268
33. Castagna L, Santoro A, Carlo-Stella C. Salvage therapy for Hodgkin’s lymphoma: a review of current regimens and outcomes. J Blood Med. 2020;11:389-403. https://doi.org/10.2147/JBM.S250581 DOI: https://doi.org/10.2147/JBM.S250581
34. Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz S, Kobos R, Kumar A, Matasar M, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Shukla N, Steinherz P, Straus D, Trippett T, Younes A, Zelenetz A, Moskowitz CH. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284–92. https://doi.org/10.1016/s1470-2045(15)70013-6 DOI: https://doi.org/10.1016/S1470-2045(15)70013-6
35. Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1 positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020;21(1):121–33. https://doi.org/10.1016/s1470-2045(19)30671-0 DOI: https://doi.org/10.1016/S1470-2045(19)30671-0
36. Cole PD, McCarten KM, Pei Q, Spira M, Metzger ML, Drachtman RA, Horton TM, Bush R, Blaney SM, Weigel BJ, Kelly KM. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin’s lymphoma (AHOD1221): a Children’s Oncology Group, multicentre single-arm, phase 1-2 trial. Lancet Oncol. 2018;19(9):1229–38. https://doi.org/10.1016/s1470-2045(18)30426-1 DOI: https://doi.org/10.1016/S1470-2045(18)30426-1
37. Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, David KA, Park S, Beaven AW, Habib A, Bachanova V, Nakhoda S, Khan N, Lynch RC, Smith SD, Ho VT, LaCasce A, Armand P, Herrera AF. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021;5(6):1648–59. https://doi.org/10.1182/bloodadvances.2020003556 DOI: https://doi.org/10.1182/bloodadvances.2020003556
38. Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II trial of high-dose Gemcitabine/Busulfan/ Melpahlan with autologous stem-cell transplantation for primary refractory or poor-risk relapsed Hodgkin’s Lymphoma. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2018;24(8):1602–9. https://doi.org/10.1016/j.bbmt.2018.02.020 DOI: https://doi.org/10.1016/j.bbmt.2018.02.020
39. Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after highdose chemotherapy: a 15-year analysis. Haematologica. 2021;107(4):899–908. https://doi.org/10.3324/haematol.2021.278311 DOI: https://doi.org/10.3324/haematol.2021.278311
40. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin’s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2013;19(3):410–7. https://doi.org/10.1016/j.bbmt.2012.10.029 DOI: https://doi.org/10.1016/j.bbmt.2012.10.029
41. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stemcell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2015;385(9980):1853–62. https://doi.org/10.1016/s0140-6736(15)60165-9 DOI: https://doi.org/10.1016/S0140-6736(15)60165-9
42. Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P,Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–42. https://doi.org/10.1182/blood-2018-07-861641 DOI: https://doi.org/10.1182/blood-2018-07-861641
43. Sureda A, André M, Borchmann P, da Silva MG, Gisselbrecht C, Vassilakopoulos TP, Zinzani PL, Walewski J. Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective. BMC Cancer. 2020;20(1):1088. https://doi.org/10.1186/s12885-020-07561-2 DOI: https://doi.org/10.1186/s12885-020-07561-2
44. Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134(1):22–9. https://doi.org/10.1182/blood.2019000215 DOI: https://doi.org/10.1182/blood.2019000215
45. Satwani P, Jin Z, Martin PL, Bhatia M, Garvin JH, George D, Chaudhury S, Talano J, Morris E, Harrison L, Sosna J, Peterson M, Militano O, Foley S, Kurtzberg J, Cairo MS. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia. 2015;29(2):448–55. https://doi.org/10.1038/leu.2014.194 DOI: https://doi.org/10.1038/leu.2014.194
46. Mariotti J, Bramanti S, Devillier R, Furst S, El Cheikh J, Sarina B, Granata A, Faucher C, Harbi S, Morabito L, Weiller PJ, Chabannon C, Mokart J, Mineri R, Carlo-Stella C, Santoro A, Blaise D, Castagna L. Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma. Bone Marrow Transplant. 2018;53(3):366–70. https://doi.org/10.1038/s41409-017-0032-1 DOI: https://doi.org/10.1038/s41409-017-0032-1
47. Claviez A, Canals C, Dierickx D, Stein J, Badell I, Pession A, Mackinnon S, Slavin S, Dalle JH, Chacón MJ, Sarhan M, Wynn RF, Suttorp M, Dini G, Sureda A, Schmitz N; Lymphoma and Pediatric Diseases Working Parties. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(10):2060–7. https://doi.org/10.1182/blood-2008-11-189399 DOI: https://doi.org/10.1182/blood-2008-11-189399
48. Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P, Bacigalupo A, Socié G, Bonifazi F, Finel H, Velardi A, Potter M, Bruno B, Castagna L, Malladi R, Russell N, Sureda A. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin’s lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol. 2016;27(12):2251–7. https://doi.org/10.1093/annonc/mdw421 DOI: https://doi.org/10.1093/annonc/mdw421
49. Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, El-Cheikh J, Granata A, Faucher C, Harbi S, Morabito L, Mariotti J, Puvinathan S, Weiller PJ, Chabannon C, Mokart D, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D. Erratum: Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone Marrow Transplant. 2017;52(5):797. https://doi.org/10.1038/bmt.2017.26 DOI: https://doi.org/10.1038/bmt.2017.26
50. Castagna L, Busca A, Bramanti S, Raiola Anna M, Malagola M, Ciceri F, Arcese W, Vallisa D, Patriarca F, Specchia G, Raimondi R, Devillier R, Furst S, Giordano L, Sarina B, Mariotti J, Olivieri A, Bouabdallah R, Carlo-Stella C, Rambaldi A, Santoro A, Corradini P, Bacigalupo A, Bonifazi F, Blaise D. Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. BMC Cancer. 2020;20(1):1140. https://doi.org/10.1186/s12885-020-07602-w DOI: https://doi.org/10.1186/s12885-020-07602-w
51. Mariotti J, Devillier R, Bramanti S, Sarina B, Furst S, Granata A, Faucher C, Harbi S, Morabito L, Chabannon C, Carlo-Stella C, Bouabdallah R, Santoro A, Blaise D, Castagna L. T Cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for Hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease compared with HLA-identical related donors. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2018;24(3):627–32. https://doi.org/10.1016/j.bbmt.2017.11.030 DOI: https://doi.org/10.1016/j.bbmt.2017.11.030
52. Gauthier J, Castagna L, Garnier F, Guillaume T, Socié G, Maury S, Maillard N, Tabrizi R, Marchand T, Malfuson J, Gac A, Gyan E, Mercier M, Béguin Y, Delage J, Turlure P, Marçais A, Nguyen S, Dulery R, Bay J, Huynh A, Daguindau E, Cornillon J, Régny C, Michallet M, Peffault de Latour R, Yakoub-Agha I, Blaise D. Reducedintensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplant. 2017;52(5):689–96. https://doi.org/10.1038/bmt.2016.349 DOI: https://doi.org/10.1038/bmt.2016.349
53. Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles- Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021;35(9):2672–83. https://doi.org/10.1038/s41375-021-01193-6 DOI: https://doi.org/10.1038/s41375-021-01193-6
54. Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(32):3794–804. https://doi.org/10.1200/jco.20.01342 DOI: https://doi.org/10.1200/JCO.20.01342
55. Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017; 127(9): 3462–71. https://doi.org/10.1172/jci94306 DOI: https://doi.org/10.1172/JCI94306
56. Daw S, Wynn R, Wallace H. Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents. Br J Haematol. 2011;152(3):249–60. https://doi.org/10.1111/j.13652141.2010.08455.x DOI: https://doi.org/10.1111/j.1365-2141.2010.08455.x
57. Colita A, Colita A, Bumbea H, Croitoru A, Orban C, Lipan LE, Craciun OG, Soare D, Ghimici C, Manolache R, Gelatu I, Vladareanu AM, Pasca S, Teodorescu P, Dima D, Lupu A, Coriu D, Tomuleasa C, Tanase A. LEAM vs. BEAM vs. CLV conditioning regimen for autologous stem cell transplantation in malignant lymphomas. Retrospective comparison of toxicity and efficacy on 222 patients in the first 100 days after transplant, on behalf of the Romanian Society for Bone Marrow Transplantation. Front Oncol. 2019;9:892. https://doi.org/10.3389/fonc.2019.00892 DOI: https://doi.org/10.3389/fonc.2019.00892
58. Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011; 118(12): 3419–25. https://doi.org/10.1182/blood-2011-04-351924 DOI: https://doi.org/10.1182/blood-2011-04-351924
59. Magalhaes-Silverman M, Lister J, Rybka W, Wilson J, Ball E. Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. Bone Marrow Transplant. 1997;19(8):777–81. https://doi.org/10.1038/sj.bmt.1700733 DOI: https://doi.org/10.1038/sj.bmt.1700733
60. Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol. 2002;81(2):96–102. https://doi.org/10.1007/s00277-001-0413-8 DOI: https://doi.org/10.1007/s00277-001-0413-8
61. Wadehra N, Farag S, Bolwell B, Elder P, Penza S, Kalaycio M, Avalos B, Pohlman B, Marcucci G, Sobecks R, Lin T, Andrèsen S, Copelan E. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2006;12(12):1343–9. https://doi.org/10.1016/j.bbmt.2006.08.039 DOI: https://doi.org/10.1016/j.bbmt.2006.08.039
62. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, Passweg J, Martino R, Valcárcel D, Besalduch J, Duarte R, León A, Pascual MJ, García-Noblejas A, López Corral L, Xicoy B, Sierra J, Schmitz N. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study – a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97(2):310–7. https://doi.org/10.3324/haematol.2011.045757 DOI: https://doi.org/10.3324/haematol.2011.045757
63. Das-Gupta E, Thomson KJ, Bloor AJC, Clark AD, Mackinnon S, Kayani I, Clifton-Hadley L, Patrick P, El- Mehidi N, Lawrie A, Kirkwood AA, Russell NH, Linch DC, Peggs KS. Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study. Blood Adv. 2019;3(24):4264–70. https://doi.org/10.1182/bloodadvances.2019001016 DOI: https://doi.org/10.1182/bloodadvances.2019001016
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Cilmara Kuwahara, Carla Nolasco Monteiro Breviglieri, Luiza Milaré, Osvaldo Alves Menezes Neto
This work is licensed under a Creative Commons Attribution 4.0 International License.
